to Advance Universal CAR-T Therapy and Strenghten France-s Biotherapy Leadership.
• Allogenica received a €2.5 million grant from the French government’s France 2030 program to support the industrialization of its breakthrough universal CAR-T therapies for blood cancers.
• Cost-effective, scalable CAR-T solutions: Allogenica, using its proprietary CAR-pre-T technology, reduces production costs by tenfold and enables large-scale production, enhancing treatment availability and making CAR-T therapy more accessible to patients globally.
• With this funding, Allogenica will collaborate with strategic partners across the 100% French ecosystem to establish a cutting-edge CAR-T biomanufacturing by 2026, strengthening France’s global leadership position and driving economic growth and job creation.